Nomura Reaffirms Neutral Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline (LON: GSK)‘s stock had its “neutral” rating reiterated by investment analysts at Nomura in a note issued to investors on Friday. They currently have a $21.78 (1340 GBX) target price on the stock.
Shares of GlaxoSmithKline opened at 1370.50 on Friday. GlaxoSmithKline has a 52 week low of GBX 1314.00 and a 52 week high of GBX 1556.50. The stock’s 50-day moving average is currently GBX 1437.31. The company’s market cap is £66.661 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, December 20th. They now have a $24.85 price target on the stock. Separately, analysts at Exane BNP Paribas reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, December 6th. They now have a $23.33 price target on the stock. Finally, analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, December 4th. They now have a $29.31 price target on the stock.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.